Full Text:   <1536>

CLC number: R764.43+7

On-line Access: 2012-02-29

Received: 2011-08-03

Revision Accepted: 2011-12-27

Crosschecked: 2012-02-16

Cited: 4

Clicked: 3453

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2012 Vol.13 No.3 P.203-208

10.1631/jzus.B1100248


Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss


Author(s):  Yao-wen Wang, Ji-hao Ren, Yong-de Lu, Tuan-fang Yin, Ding-hua Xie

Affiliation(s):  Otolaryngology-Head and Neck Surgery Department, Ningbo First Hospital, Ningbo 315000, China; more

Corresponding email(s):   jihao5114@sina.com

Key Words:  Sudden sensorineural hearing loss, Dexamethasone, Intratympanic, Round window


Yao-wen Wang, Ji-hao Ren, Yong-de Lu, Tuan-fang Yin, Ding-hua Xie. Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss[J]. Journal of Zhejiang University Science B, 2012, 13(3): 203-208.

@article{title="Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss",
author="Yao-wen Wang, Ji-hao Ren, Yong-de Lu, Tuan-fang Yin, Ding-hua Xie",
journal="Journal of Zhejiang University Science B",
volume="13",
number="3",
pages="203-208",
year="2012",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1100248"
}

%0 Journal Article
%T Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss
%A Yao-wen Wang
%A Ji-hao Ren
%A Yong-de Lu
%A Tuan-fang Yin
%A Ding-hua Xie
%J Journal of Zhejiang University SCIENCE B
%V 13
%N 3
%P 203-208
%@ 1673-1581
%D 2012
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1100248

TY - JOUR
T1 - Evaluation of intratympanic dexamethasone for treatment of refractory sudden sensorineural hearing loss
A1 - Yao-wen Wang
A1 - Ji-hao Ren
A1 - Yong-de Lu
A1 - Tuan-fang Yin
A1 - Ding-hua Xie
J0 - Journal of Zhejiang University Science B
VL - 13
IS - 3
SP - 203
EP - 208
%@ 1673-1581
Y1 - 2012
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1100248


Abstract: 
Objective: To observe and compare the efficacy of intratympanic application of dexamethasone (DXM) for the treatment of refractory sudden sensorineural hearing loss (SSNHL), the DXM was given in three different ways: by tympanic membrane injection, by drip through a ventilation tube, and by perfusion through a round window catheter. Methods: We conducted a nonrandomized retrospective clinical trial involving 55 patients with refractory SSNHL. For 21 patients (the perfusion group), DXM (2.5 mg/0.5 ml) was perfused transtympanically through a round window catheter using an infusion pump for 1 h twice a day for 7 d giving a total amount of 35.0 mg. For 23 patients (the injection group), DXM (2.5 mg/time) was injected by tympanic membrane puncture at intervals of 2 d on a total of four occasions giving a total amount of 10.0 mg. For 11 patients (the drip group), DXM (2.5 mg/0.5 ml) was dripped via a ventilation tube placed by myringotomy, once on the first day and twice a day for the remaining 6 d giving a total amount of 32.5 mg. Thirty-two patients with refractory SSNHL who refused to undertake further treatments were defined as the control group. Hearing recovery and complications were compared among the groups. Hearing results were evaluated based on a four-frequency (0.5, 1.0, 2.0, 4.0 kHz) pure tone average (PTA). Results: Post-treatment audiograms were obtained one month after treatments were completed. The improvements in average PTA for the perfusion, injection, and drip groups were 9.0, 8.6, and 1.7 dB, respectively. Hearing improvement was significantly greater in the perfusion and injection groups than in the control group (1.4 dB) (P<0.05). In the perfusion group, 8 out of 21 patients (38.1%) had a PTA improvement of 15‒56 dB (mean 29.8 dB); in the injection group, 8 out of 23 patients (34.8%) had a PTA improvement of 16‒54 dB (mean 24.9 dB); in the drip group, 1 of 11 patients (9.1%) had a PTA improvement of 26.0 dB; in the control group, 3 out of 32 patients (9.4%) had a PTA improvement of 15‒36 dB (mean 14.9 dB). Conclusions: Topical intratympanic application of DXM is a safe and effective method for the treatment of SSNHL cases that are refractory to conventional therapies.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Banerjee, A., Parnes, L.S., 2005. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol. Neurotol., 26(5):878-881.

[2]Barrs, D.M., 2004. Intratympanic corticosteroids for Meniere’s disease and vertigo. Otolaryngol. Clin. North Am., 37(5):955-972.

[3]Chen, C.Y., Halpin, C., Rauch, S.D., 2003. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol. Neurotol., 24(5):728-733.

[4]Choung, Y.H., Park, K., Shin, Y.R., Cho, M.J., 2006. Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope, 116(5):747-752.

[5]Dodson, K.M., Sismanis, A., 2004. Intratympanic perfusion for the treatment of tinnitus. Otolaryngol. Clin. North Am., 37(5):991-1000.

[6]Fetterman, B.L., Saunders, J.E., Luxford, W.M., 1996. Prognosis and treatment of sudden sensorineural hearing loss. Am. J. Otol., 17(4):529-536.

[7]Gianoli, G.J., Li, J.C., 2001. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol. Head Neck Surg., 125(3):142-146.

[8]Haynes, D.S., O′Malley, M., Cohen, S., Watford, K., Labadie, R.F., 2007. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 117(1):3-15.

[9]Herr, B.D., Marzo, S.J., 2005. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 132(4):527-531.

[10]Hughes, G.S., Freedman, M.A., Haberkamp, T.J., Guay, M.E., 1996. Sudden sensorineural hearing loss. Otolaryngol. Clin. North Am., 29(3):393-405.

[11]Jeyakumar, A., Frencis, D., Doerr, T., 2006. Treatment of idiopathic sudden sensorineural hearing loss. Acta Otolaryngol., 126(7):708-713.

[12]Kopke, R., Hoffer, M., Wester, D., 2001. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol. Neurotol., 22(4):475-479.

[13]Lefebvre, P.P., Staecker, H., 2002. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol., 122(7):698-702.

[14]Lu, Y.D., Ren, J.H., Wu, W.J., Yin, T.F., Tang, Y.Y., Xie, D.H., 2006. Intratympanic dexamethasone for sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:11-12 (in Chinese).

[15]Parnes, L.S., Sun, A.H., Freeman, J., 1999. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope, 109(s91):1-17.

[16]Rauch, S.D., 2004. Intratympanic steroids for sensorineural hearing loss. Otolaryngol. Clin. North Am., 37(5):1061-1074.

[17]Ren, J.H., Lu, Y.D., Yin, T.F., Liu, B., Ge, Y.L., 2006. Intratympanic dexamethasone injection for intractable sudden sensorineural hearing loss. J. Clin. Otorhinolaryngol., 20:219-221 (in Chinese).

[18]Roebuck, J., Chang, C.Y., 2006. Efficacy of steroid injection on idiopathic sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 135(2):276-279.

[19]Wilson, W.R., Byl, F.M., Laird, N., 1980. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch. Otolaryngol., 106(12):772-776.

[20]Zadeh, M.H., Storper, I.S., Spitzer, J.B., 2003. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol. Head Neck Surg., 128(1):92-98.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE